Ke Wang

Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study.

SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study.

Journal: American journal of hematology

Published: April 21, 2026

Single-Cell Landscape Change in Cervical Epithelial Cells and Microenvironment During the Transformation from CINIII to Cervical Squamous Cell Carcinoma.

Single-Cell Landscape Change in Cervical Epithelial Cells and Microenvironment During the Transformation from CINIII to Cervical Squamous Cell Carcinoma.

Journal: Cancers

Published: April 11, 2026

Lactate-to-albumin ratio as an independent predictor of short- and long-term mortality in ICU patients with malignant tumors: A retrospective cohort study.

Lactate-to-albumin ratio as an independent predictor of short- and long-term mortality in ICU patients with malignant tumors: A retrospective cohort study.

Journal: Oncology letters

Published: February 22, 2026

Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial.

Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial.

Journal: Therapeutic advances in medical oncology

Published: September 21, 2025

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Journal: CA: a cancer journal for clinicians

Published: September 15, 2025

Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer.

Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer.

Journal: Signal transduction and targeted therapy

Published: September 14, 2025

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors.

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors.

Journal: Experimental hematology & oncology

Published: July 24, 2025

Real-World Experience of Niraparib as Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer: A Single-Center Retrospective Study.

Real-World Experience of Niraparib as Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer: A Single-Center Retrospective Study.

Journal: OncoTargets and therapy

Published: May 20, 2025

Characteristics and patient-reported outcomes of long-term cancer survivors after apatinib-based therapy: an online survey.

Characteristics and patient-reported outcomes of long-term cancer survivors after apatinib-based therapy: an online survey.

Journal: BMC cancer

Published: May 24, 2024

Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.

Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.

Journal: Nature medicine

Published: November 17, 2023

RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter.

RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter.

Journal: Journal of cellular and molecular medicine

Published: July 19, 2023

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.

Journal: BMC medicine

Published: March 11, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026